Prostate and Bladder
Our major focus is to address areas of major clinical unmet need in each disease through inter-disciplinary, project-focused teams comprising cell biologists, radiation biologists, medicinal chemists, pathologists, clinical oncologists and urologists. The objective of the Group is to innovate clinical practice in Genito-Urinary Cancers by increasing the portfolio of trials-based and clinical research activity. Clinical activity is prioritized to projects where there is an unmet clinical need, where we can undertake a national leadership role and where biomarker development or validation is an integral component of the trial design. The clinically-relevant questions that we have adopted in these diseases are:
- To promote molecularly-stratified approaches that identify high risk patients;
- To characterize novel therapeutic strategies and accompanying biomarkers for molecular stratified, high-risk groups;
- To identify increasingly effective treatments of advanced castrate-resistant prostate cancer, especially in the context of bone metastasis;
- To characterize novel therapeutic strategies and biomarkers of radio-resistant prostate cancers.
- To characterize the mechanism of radiation-induced bystander responses in bladder transitional cell carcinoma and normal urothelium;
- To investigate the mechanisms underpinning toxicity in normal bladder post-irradiation;
- To characterize novel therapeutic strategies for treatment of radiation-induced bladder dysfunction.